ENTX Stock Analysis: Buy, Sell, or Hold?
ENTX - Entera Bio Ltd. Ordinary Shares
$3.42
0.19 (5.88%)
▲
5d:
+17.93%
30d:
+66.83%
90d:
+175.81%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When ENTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ENTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ENTX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ENTX is currently trading at $3.42, which is considered extended relative to its 30-day fair value range of $2.33 to $3.29.
Technical Outlook: Technically, ENTX is in a strong uptrend. The price is approaching resistance at $3.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+163.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENTX is in a strong uptrend. The price is approaching resistance at $3.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $9.00 (+163.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.33 -
$3.29
Company Quality Score
49/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
61.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 163.2% below Wall St target ($9.00)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.33 -
$3.29
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.45
(13.1%)
Support & Resistance Levels
Support Level
$2.75
Resistance Level
$3.47
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.00
Wall Street Target
$9.00
(+163.2%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 25, 2026 5:13 AM ET
Data refreshes hourly during market hours. Next update: 6:13 AM
Data refreshes hourly during market hours. Next update: 6:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENTX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Geno J Germano
BUY
20000 shares
2026-03-09
Sean Ellis
BUY
10000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 32 SELL |
